This study is not accepting new patients

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

a study on Lung Cancer Non-Small Cell Lung Cancer Thyroid Cancer Colon Cancer Colorectal Cancer Breast Cancer Pancreatic Cancer Solid Tumor

Summary

at UCSF
study started
Alain Algazi, MD(ucsf)

Description

Summary

Expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.

Details

N/A for expanded access

Keywords

Non Small Cell Lung Cancer Medullary Thyroid Cancer Colon Cancer Breast Cancer Pancreatic Cancer Papillary Thyroid Cancer Other Solid Tumors With Evidence of Activating RET Alteration Thyroid Neoplasms Thyroid Cancer, Papillary Thyroid Diseases LOXO-292

Eligibility

You can join if…

  • Diagnosis of cancer with RET activation, who are not eligible for an ongoing LOXO-292 clinical trial and are medically suitable for treatment with LOXO-292

You CAN'T join if...

  • Currently enrolled in an ongoing clinical study of LOXO-292 or another RET inhibitor

Locations

  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco California 94158 United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas Nevada 89169 United States

Lead Scientist

  • Alain Algazi, MD (ucsf)
    Associate Professor, Medicine. Authored (or co-authored) 54 research publications

Details

Status
not accepting new patients
Start Date
Sponsor
Loxo Oncology, Inc.
ID
NCT03906331
Study Type
Expanded Access
Last Updated